Total revenue from clinical diagnostics customers increased 19.2% over prior year quarter, or 14.8% in constant currency. Within Clinical Diagnostics, Immunoassay was up more than 23% and autochemistry was up 16%. Cellular was up more than 19%, with the flow cytometry products acquired from Dako contributing 3.1% to this growth. Clinical automation continued its momentum in the market growing almost 28% in the quarter. (See Revenue by Segment summary. Segments have been realigned to provide more visibility of Clinical Diagnostics and Life Sciences businesses.)
Revenue from life sciences customers increased 18.3% when compared to prior year, or 12.8% in constant currency. Increased demand in centrifugation and life sciences automation contributed to this growth, each up over 20%.
Recurring revenue continued its steady growth, increasing nearly 13% to $574.9 million, or 78.7% of total revenue. Above-market growth in Immunoassay continued with recurring revenue in Access-family Immunoassay up 22.4%, or 17.5% in constant currency.
Cash instrument sales were up considerably in the period, increasing
$51.7 million over prior year quarter. China, India and emerging markets,
where instrument sales doubled in the period, contributed to this increase.
Heightened instrument sales in Cellular, up 50% in the quarter, were driven
in part by an increase in production, helping the company to overcome a
previously disclosed supply chain disruption. Life Sciences instrument
revenue increased 29% compared to a
|SOURCE Beckman Coulter, Inc.|
Copyright©2008 PR Newswire.
All rights reserved